Zhenyi Jin

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Acute Myeloid Leukemia

Aqueous Solution

Top Venues

BioMed research international

ImmunoTargets and therapy

Immunological investigations

Clinical and experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yuchen Li, Yinfeng Gu, Pengyue Yang, Yan Wang, Xibao Yu, Yangqiu Li, Zhenyi Jin, Ling Xu
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer. ImmunoTargets and therapy 13 (2024)
Yuchen Li, Yinfeng Gu, Pengyue Yang, Yan Wang, Xibao Yu, Yangqiu Li, Zhenyi Jin, Ling Xu
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer. ImmunoTargets and therapy 13 (2024)
Dan Qiu, Xiaxin Liu, Wandi Wang, Xuan Jiang, Xiaofang Wu, Jiamian Zheng, Kai Zhou, Xueting Kong, Xiuli Wu, Zhenyi Jin
TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clinical and experimental medicine (2022)
Danlin Yao, Ling Xu, Lian Liu, Xiangbo Zeng, Juan Zhong, Jing Lai, Runhui Zheng, Zhenyi Jin, Shaohua Chen, Xianfeng Zha, Xin Huang, Yuhong Lu
Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia. BioMed research international 2020 (2020)
Zhenyi Jin, Tianbi Lan, Yun Zhao, Jinxia Du, Jie Chen, Jing Lai, Ling Xu, Shaohua Chen, Xueyun Zhong, Xiuli Wu, Yangqiu Li
Higher TIGIT+CD226- γδ T cells in Patients with Acute Myeloid Leukemia. Immunological investigations (2020)
Zhenyi Jin, Wanyi Ye, Tianbi Lan, Yun Zhao, Xiaxin Liu, Jie Chen, Jing Lai, Shaohua Chen, Xueyun Zhong, Xiuli Wu
Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients. BioMed research international 2020 (2020)
Yan Xu, Ling Xu, Cunte Chen, Yi-Kai Zhang, Chengwu Zeng, Zhenyi Jin, Shaohua Chen, Bo Li, Xianfeng Zha, Zhinan Yin, Yangqiu Li
Age-Related Immune Profile of the T Cell Receptor Repertoire, Thymic Recent Output Function, and miRNAs. BioMed research international 2020 (2020)